Research by DealForma
Decades of context backed by data from the DealForma databaseRun your analyses better, in less time, with the newest database built for biopharma, medtech, and diagnostics.
Neurology Venture Activity Through Q2 2023
Quarterly venture investment activity into...
Cerebral Alliances: A Closer Look At Neurology R&D Partnerships In H1 2023
We are tracking the biopharma R&D...
August 2023 Top Biopharma Deal: Poseida license option deal with Astellas for P-MUC1C-ALLO1
21,135
Licensing Deals
4,145
M&A
5,766
Other Deals
21,479
Funding Rounds
34,717
Company Profiles
26,805
Drug Sales Figures
All of this by stage, disease indication, modality, target…
Biopharma IPO Watch: Therapeutics & Platforms
Biopharma IPO activity was still quiet through the second quarter 2023 with 3 companies going public on global exchanges for a total of $800 million. This follows 3 IPOs in the first quarter at $400 million. Among these IPOs, Laekna raised approximately $101 million...
Q2 2023 Biopharma Venture Funding – Therapeutics and Platforms
The biopharmaceutical industry experienced a return of venture funding activity in the second quarter of 2023, driving therapeutic development and platform technology advancements. ElevateBio secured a noteworthy $401 million Series D financing to further develop...
Q2 2023 Review Of R&D Partnerships For Biopharma Therapeutics & Platforms
Biopharma licensing activity in Q2 2023 was the lowest since 2019. Development and commercialization deals for the quarter came in at 110 deals for a total announced value of $28.2 billion with $1.2 billion in total upfront cash and equity. There were notable deals...
M&A In Biopharma Therapeutics & Platforms – Q2 2023
Biopharma M&A activity in Q2 2023 picked up as the number of therapeutics and discovery platform company acquisitions tracked higher. The second quarter of 2023 saw 27 M&A deals for a total upfront of $27.4 billion or $28.1 billion when counting contingent...
Healthcare & Life Sciences Sector: Quarterly Overview
The biopharmaceutical industry outlook for the new quarter remains dynamic and promising, characterized by significant deals in the first half. Galderma's private placement of $1 billion aims to strengthen its dermatology position and leverage its integrated strategy....
July 2023 Top Biopharma Deal: Alnylam co-development and co-commercialization deal with Roche for zilebesiran
Neurology M&A Snapshot Through Q2 2023
We are looking at mergers and acquisitions in the neurology space through June 2023. As with the broader biopharma sector, neurology deal flow has been down since 2020. The year started with a decent number of billion-plus acquisitions in other biopharma therapeutic...
June 2023 Top Biopharma Deal: AstraZeneca research partnership with Quell Therapeutics with an option to license Treg cell therapies
Mergers and Acquisitions in Dermatology: Q1 2023 Market Performance
The M&A landscape in the dermatology sector illustrates an enticing market that attracts ongoing investment. Analyzing the data from the past three years reveals a consistent level of activity, suggesting mergers and acquisitions in dermatology are seeing...
R&D Partnerships by TA – Autoimmune
So far, 2023 has witnessed a mixed landscape for R&D partnerships in the autoimmune sector. While there were notable activities and collaborations, there was a decline in the number of deals and the overall value compared to previous years. This suggests a...
R&D Partnerships – Medtech – Q1 2023
Medtech R&D partnerships play a significant role in driving innovation and advancements in healthcare. Medtech's various focus areas, such as medical devices, digital health solutions, and wearable technologies, saw active collaboration and investment, but deal...
May 2023 Top Biopharma Deal: Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...
M&A – Biopharma Therapeutics And Platforms – Q1 2023
Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna's acquisition of OriCiro Genomics for $85 million, expanding Moderna's manufacturing capabilities for mRNA vaccines. Pfizer's blockbuster $43 billion acquisition...
R&D Partnerships – Biopharma Therapeutics And Platforms – Q1 2023
First quarter 2023 R&D partnerships for biopharma therapeutics and platforms followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 2023 numbers was biopharma M&A,...
Biopharma Venture & IPOs – Therapeutics and Platforms: Q1 2023 Review
The slowdown in interest rate hikes may increase small biotech companies' initial public offerings (IPOs) later in 2023. Investors will be more cautious and favor firms with drugs in human trials. The biotech industry experienced a decline in IPOs globally in 2022 due...
Healthcare and Life Sciences Q1 2023 Review: Licensing Partnerships
There has been a significant decrease in R&D licensing and partnership activity from the previous quarter, dropping from $55.9 billion to $35.4 billion in Q1 2023. Q1 2023 R&D Partnerships Set to Drive Growth $35.4 billion in total R&D partnership deal...
Healthcare and Life Sciences Q1 2023 Review: IPOs and SPACs
Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs Only $400 million in 3 newly filed IPOs were raised in Q1 2023 - 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022. Q2 of 2021 saw the most...
April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer
Healthcare and Life Sciences Q1 2023 Review: Venture Capital
Venture capital investment activity in Q1 2023 was down across multiple industries, including biopharma. Biopharma venture fundraising looked much like 2022, which looked much like 2019. As before, biopharma fared slightly better than medtech, diagnostics, tools, and...
Healthcare and Life Sciences Q1 2023 Review: Mergers & Acquisitions
First quarter 2023 deal activity followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 numbers was biopharma M&A, mainly driven by early January acquisition activity...
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
March 2023 Top Biopharma Deal: OncoC4 – BioNTech for ONC-392 for Solid Tumors and NSCLC
Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer The pharmaceutical industry continues to place significant emphasis on cancer treatment. A report by the International Agency for Cancer Research suggests that the number of deaths resulting from...
Venture & IPO – Medtech
Venture & IPO - Medtech As the demand for innovative medical technologies continues to grow, many entrepreneurs and investors are exploring ways to finance the development and commercialization of new MedTech products. Two popular options for raising capital in...
M&A – Medtech
M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...
R&D Partnerships – Medtech
R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...
Biopharma Reverse Mergers And SPACs– What Happened Since 2020
Biopharma Reverse Mergers And SPACs– What Happened Since 2020 The biopharmaceutical industry has seen a significant uptick in using reverse mergers and Special Purpose Acquisition Companies (SPACs) to go public since 2020. This trend has been partly driven by the...
M&A – Biopharma Therapeutics And Platforms
M&A – Biopharma Therapeutics And Platforms Mergers and Acquisitions are related concepts that refer to consolidating two or more companies into a single entity. In a merger, two or more companies come together to form a new company, while in an acquisition, one...
R&D Partnerships – Biopharma Therapeutics And Platforms
R&D Partnerships - Biopharma Therapeutics And Platforms R&D partnerships are common in the biopharmaceutical industry. Typically, these partnerships involve two or more companies or organizations collaborating to research, develop, and commercialize new drugs...
February 2023 Top Biopharma Deal: Axsome – Pharmanovia for EDS Drug Sunosi
January 2023 Top Biopharma Deal: Hutchmed – Takeda for cancer drug fruquintinib
Biopharma Therapeutics & Platforms Paradigm
Biopharma Therapeutics & Platforms Paradigm Biopharmaceutical companies that develop new therapies and health technologies are essential for advancing drug development in its early stages. That's why US biotech firms are highly sought after by private equity...
2022 Year in Review and Future Insights
The recent decline in U.S. GDP and the risk of recession are significant factors affecting the biopharma sector. The capital markets for biopharma assets are challenging, with difficulties in valuations, accessing the IPO market, and raising new capital. The closing...
December 2022 Top Biopharma Deal: Akeso – Summit for Cancer Drug Ivonescimab
November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003
October 2022 Top Biopharma Deal: MacroGenics – Gilead for blood cancer drug MGD024
September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep
August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245
July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208
June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libtayo
May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation
April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment
March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation
February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment
